Cost-benefit Analyses
Because patients in I-MORE had fewer days with sickness absence, the production loss was lower for I-MORE compared to O-ACT; during the two years of follow-up, the benefit from higher production was 14,725 euros (95% CI -1,925 to 31,375). Since the extra total health care costs (intervention costs plus other healthcare use) was 12,057 euros (95% CI 9,181 to 14,933), the net societal benefit of I-MORE was 2,667 euros in favour of I-MORE. Bootstrapped estimates showed a mean cost benefit of 2,877 euros, with confidence bounds between − 13,589 and 19,616. Among all bootstrapped estimates, 64% were above zero, thus, in favour of I-MORE.